COAG
Hemab Therapeutics Holdings, Inc.
Set alert
41.45 USD +1.03 +2.55%
39.38 Day range 42.85
24.98 52-week range 54.94
- YTD
- +21.91%
- 1 year
- +21.91%
- Open
- 40.34
- Prev close
- 40.42
- Mkt cap
- 1.94B
- Vol
- 765.62K
- Avg vol
- 454.15K
- EPS
- -4.33
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 39.38
- High
- 42.85
- Forward P/E
- -16.20
- Beta
- 0.00
- Short ratio
- 5.27
- Inst. own
- 92.50%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 10, 2026
- 50-d avg
- 38.04
- 200-d avg
- 36.74
- 1y target
- 62.67
Key statistics
- Market cap
- 1.93B
- Enterprise value
- 1.43B
- Trailing P/E
- 0.00
- Forward P/E
- -16.20
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.24
- EPS (TTM)
- -4.33
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 457.46M
- Total debt
- 1.03M
- Return on equity
- 0.00%
- Shares outstanding
- 46.71M
- Short % of float
- 0.00%
- 50-day average
- 38.04
- 200-day average
- 36.74
Analyst view
Consensus: none
Price target (mean) 62.67 +51.2% upside
Now 41.45
- Target (low)
- 58.00
- Target (mean)
- 62.67
- Target (high)
- 70.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 10, 2026
Expected Nov 10, 2026. Consensus EPS estimate -0.51529.
Financials — quick view
COAG Revenue — quarterly 0
COAG Net income — quarterly -24.15M
COAG EPS — quarterly -0.80
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 10, 2026 | Sep 30, 2026 | -0.51 | — | — | — |
| Aug 11, 2026 | Jun 30, 2026 | -0.7325 | -0.80 | -0.07 | -9.22% |
| May 21, 2026 | Mar 31, 2026 | -23.25 | -23.98 | -0.73 | -3.16% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 15, 2026 | JP Morgan | init | — | Overweight |
| Oct 12, 2026 | Rodman & Renshaw | init | — | Buy |
| Aug 12, 2026 | Wedbush | main | Outperform | Outperform |
| Aug 11, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 13, 2026 | Jefferies | main | Buy | Buy |
| Jul 13, 2026 | Wedbush | main | Outperform | Outperform |
About Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- hemab.com
News
- JP Morgan Initiates Coverage On Hemab Therapeutics Hldgs with Overweight Rating, Announces Price Target of $70
- Rodman & Renshaw Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $56
- Hemab Therapeutics (NASDAQ:COAG) Shares Gap Down – Here’s What Happened
- Hemab Therapeutics (NASDAQ:COAG) Sees Strong Trading Volume – Should You Buy?
- Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives Consensus Rating of “Moderate Buy” from Analysts
- Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert
- Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding
- Why Webuy Global Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
- Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target to $64
- HC Wainwright & Co. Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $60
Your note
Sign in to keep a note on COAG — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| MARAGANORE JOHN M | Director | Conversion of Exercise of derivative security | May 3, 2026 | 35,948 |
| NOVO HOLDINGS A/S | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | May 3, 2026 | 4,180,550 |
| RA CAPITAL HEALTHCARE FUND,L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 11, 2026 | 0 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 15, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 16.72% | 7,808,627 | 322.18M | Jun 29, 2026 |
| Novo Holdings A/S | 8.95% | 4,180,550 | 172.49M | Jun 29, 2026 |
| FMR, LLC | 7.92% | 3,697,837 | 152.57M | Jun 29, 2026 |
| Capital International Investors | 7.72% | 3,603,876 | 148.70M | Jun 29, 2026 |
| Deep Track Capital, Lp | 7.71% | 3,602,093 | 148.62M | Jun 29, 2026 |
| Siren, L.L.C. | 4.47% | 2,086,834 | 86.10M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SmallCap World Fund Inc | 7.51% | 3,506,543 | 144.68M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.19% | 555,543 | 22.92M | Jun 29, 2026 |
| JPMorgan Trust II-JPMorgan Small Cap Growth Fund | 1.14% | 531,382 | 21.92M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.12% | 523,853 | 21.61M | Aug 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.10% | 514,858 | 21.24M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.08% | 506,791 | 20.91M | Sep 29, 2026 |